Bolt Biotherapeutics (BOLT) reported Q2 2026 results, with operating loss narrowing to $8.4 million from $9.2 million as R&D and G&A expenses declined. Its lead program, BDC-4182, continues in a Phase 1/2 study for gastric and gastroesophageal cancer, with initial clinical data expected alongside Q3 results.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.